Immupharma Plc (IMM) Ordinary 1p
- Add to watchlist
- Create an alert
- This stock can be held in a
2.21p
2.37p
3.78p
£9.49 million
2.30p
2.20p
0.83p
n/a
0.04p (1.55%) Previous:
0.04p
734,558
n/a
150,000
Performance
Not available for this stock.
Fundamental data
Year ending: | 31/12/2022 | 31/12/2021 |
---|---|---|
Revenue (£m) | n/a | 0.12 |
Profit before tax (£m) | (4.46) | (8.94) |
Adjusted EPS (p): | (1.26) | (3.25) |
P/E ratio | n/a | n/a |
PEG | n/a | n/a |
EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: British pound
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
ImmuPharma progresses P140 clinical programme with FDA
12 April 2023 14:13
-
ImmuPharma upbeat after meeting with US partner Avion
11 November 2022 13:04
-
ImmuPharma's US partner receives FDA response on Lupuzor
14 September 2022 13:51
-
New intellectual property strategy initiated
2 April 2024 07:03
-
Incanthera provides Comm'l Update/Revenue F'casts
25 March 2024 07:25
-
Grant of Share Options
19 March 2024 07:00
Recent trade data is unavailable. We will be replacing it, however in the meantime the information is available on the London Stock Exchange website.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.